| 1 |
33853293 | Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia. | 2022 Apr 1 |
1 |
| 2 |
34173723 | A novel polyethylene glycol (PEG)-drug conjugate of Venetoclax, a Bcl-2 inhibitor, for treatment of acute myeloid leukemia (AML). | 2022 Mar |
1 |
| 3 |
34332791 | Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax. | 2022 Feb |
1 |
| 4 |
34728569 | Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas. | 2022 Jan |
2 |
| 5 |
34795418 | Inhibitors of Bcl-2 and Bruton's tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models. | 2022 Apr |
1 |
| 6 |
35185150 | Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. | 2022 Feb 21 |
2 |
| 7 |
35187951 | PALVEN: phase Ib trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancer. | 2022 May |
1 |
| 8 |
35188042 | Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells. | 2022 Feb 20 |
1 |
| 9 |
35193595 | BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion. | 2022 Feb 22 |
1 |
| 10 |
35241842 | Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. | 2022 Mar |
1 |
| 11 |
35245447 | The proteogenomic subtypes of acute myeloid leukemia. | 2022 Mar 14 |
1 |
| 12 |
35352453 | Dual targeting of PI3K and BCL-2 overcomes ibrutinib resistance in aggressive mantle cell lymphoma. | 2022 May |
1 |
| 13 |
35383271 | Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells. | 2022 Jun |
1 |
| 14 |
35443750 | The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA. | 2022 Apr 20 |
1 |
| 15 |
35454865 | Mitochondrial Kv1.3 Channels as Target for Treatment of Multiple Myeloma. | 2022 Apr 13 |
1 |
| 16 |
35491624 | Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics. | 2022 May 2 |
1 |
| 17 |
35515507 | Age-Adjusted Schedules of Venetoclax and Hypomethylating Agents to Treat Extremely Elderly Patients with Acute Myeloid Leukemia. | 2022 |
1 |
| 18 |
35577568 | The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies. | 2022 Jul |
1 |
| 19 |
35594184 | How do we manage t(11;14) plasma cell disorders with venetoclax? | 2022 May 20 |
1 |
| 20 |
35598030 | Progress in understanding the mechanisms of resistance to BCL-2 inhibitors. | 2022 May 21 |
1 |
| 21 |
32199933 | Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: A case report and review of literature. | 2021 Sep |
4 |
| 22 |
32887697 | Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade. | 2021 Jan |
1 |
| 23 |
33121235 | Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440). | 2021 Nov 1 |
2 |
| 24 |
33318657 | Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax. | 2021 Mar |
1 |
| 25 |
33368455 | Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. | 2021 Apr 1 |
1 |
| 26 |
33459064 | Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer? | 2021 Feb |
1 |
| 27 |
33480649 | Venetoclax and Decitabine in Pediatric Refractory T-cell Lymphoblastic Lymphoma. | 2021 Oct 1 |
1 |
| 28 |
33495184 | Plasma cell leukaemia with t(11;14) not responsive to venetoclax. | 2021 Jan 25 |
1 |
| 29 |
33542074 | Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies. | 2021 Apr 15 |
2 |
| 30 |
33687436 | Glycine ameliorates mitochondrial dysfunction caused by ABT-199 in porcine oocytes. | 2021 Apr 1 |
1 |
| 31 |
33743079 | New Treatment Options for Older Patients with Acute Myeloid Leukemia. | 2021 Mar 20 |
1 |
| 32 |
33846811 | Synergistic effects of LY294002 and ABT199 on the cell cycle in K562, HL60 and KG1a cells. | 2021 Jun |
2 |
| 33 |
33900450 | Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma. | 2021 Jun |
1 |
| 34 |
33919958 | Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience. | 2021 Apr 14 |
1 |
| 35 |
33926484 | Inhibition of CPT1a as a prognostic marker can synergistically enhance the antileukemic activity of ABT199. | 2021 Apr 29 |
2 |
| 36 |
34012921 | Escape From Treatment; the Different Faces of Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia. | 2021 |
1 |
| 37 |
34036969 | Venetoclax nanomedicine alleviates acute lung injury via increasing neutrophil apoptosis. | 2021 Jul 7 |
1 |
| 38 |
34112754 | Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML. | 2021 Jun 10 |
1 |
| 39 |
34331013 | Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss. | 2021 Sep |
1 |
| 40 |
34424320 | The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia. | 2021 Aug 24 |
3 |
| 41 |
34426943 | How to Sequence Therapies in Waldenström Macroglobulinemia. | 2021 Aug 23 |
1 |
| 42 |
34581757 | Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma. | 2021 Nov 23 |
1 |
| 43 |
34614506 | Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. | 2021 Dec 28 |
1 |
| 44 |
31123034 | Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. | 2020 Mar |
1 |
| 45 |
31171817 | Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas. | 2020 Jan |
1 |
| 46 |
31533509 | Mechanisms of intrinsic and acquired resistance to venetoclax in B-cell lymphoproliferative disease. | 2020 Feb |
2 |
| 47 |
31837377 | Autophagic HuR mRNA degradation induces survivin and MCL1 downregulation in YM155-treated human leukemia cells. | 2020 Jan 15 |
1 |
| 48 |
31928108 | A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma. | 2020 May |
1 |
| 49 |
31932844 | Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. | 2020 Mar 12 |
1 |
| 50 |
32035785 | Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. | 2020 Apr |
1 |